Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-09
2006-05-09
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S058200, C544S058500, C544S079000, C544S131000, C544S140000, C546S275400, C546S256000, C546S205000, C548S312400, C548S365400
Reexamination Certificate
active
07041669
ABSTRACT:
Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I):wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 4105766 (1978-08-01), Alexander
patent: 4435567 (1984-03-01), Lugosi et al.
patent: 5162360 (1992-11-01), Creswell
patent: 5686455 (1997-11-01), Adams et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: 5777097 (1998-07-01), Lee et al.
patent: 5783664 (1998-07-01), Lee et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 5869043 (1999-02-01), McDonnell et al.
patent: 5871934 (1999-02-01), Lee et al.
patent: 5916760 (1999-06-01), Goeddel et al.
patent: 5948885 (1999-09-01), Stein et al.
patent: 6242453 (2001-06-01), Cirillo et al.
patent: 6319921 (2001-11-01), Cirillo et al.
patent: 6344476 (2002-02-01), Ranges et al.
patent: 293 352 (1991-08-01), None
patent: 0 272 866 (1988-06-01), None
patent: 0 395 144 (1990-10-01), None
patent: 0 418 071 (1991-03-01), None
patent: 0692483 (1996-01-01), None
patent: 0859054 (1998-08-01), None
patent: 0922762 (1999-06-01), None
patent: 0 955 293 (1999-10-01), None
patent: 61228444 (1986-10-01), None
patent: WO 93/24458 (1993-09-01), None
patent: WO 94/18170 (1994-08-01), None
patent: WO 94/22866 (1994-10-01), None
patent: WO 96/25157 (1996-08-01), None
patent: WO 96/40143 (1996-12-01), None
patent: WO 97/16442 (1997-05-01), None
patent: WO 97/22704 (1997-06-01), None
patent: WO 97/33883 (1997-09-01), None
patent: WO 97/35855 (1997-10-01), None
patent: WO 97/35856 (1997-10-01), None
patent: WO 97/44467 (1997-11-01), None
patent: WO 97/47618 (1997-12-01), None
patent: WO 97/48697 (1997-12-01), None
patent: WO 98/07425 (1998-02-01), None
patent: WO 98/15618 (1998-04-01), None
patent: WO 98/27098 (1998-06-01), None
patent: WO 98/52558 (1998-11-01), None
patent: WO 98/52559 (1998-11-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/23091 (1999-05-01), None
patent: WO 99/32106 (1999-07-01), None
patent: WO 99/32110 (1999-07-01), None
patent: WO 99/32111 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 99/46244 (1999-09-01), None
patent: WO 00/41698 (2000-07-01), None
patent: WO 00/43384 (2000-07-01), None
patent: WO 00/55139 (2000-09-01), None
patent: WO 00/55152 (2000-09-01), None
patent: WO 01/04115 (2001-01-01), None
patent: WO 01/36403 (2001-05-01), None
patent: WO 02/066442 (2002-08-01), None
patent: WO 02/083628 (2002-10-01), None
patent: WO 02/092576 (2002-11-01), None
patent: WO 02/096876 (2002-12-01), None
patent: WO 02/098869 (2002-12-01), None
patent: WO 03/005999 (2003-01-01), None
International Search Report Jun. 30, 2003.
Polmar. S. et al: Safety and Pharmacokinetics of an oral p38 MAP Kinase Inhibitor (BIRB 796 BS), Administered twice daily for 14 days to healthy volunteers. Journal of Allergy and Clinical Immunology Online, Jan. 2002, Part 2, vol. 109, No. 1.
Gupta, A. et al: Safety, Pharmacokinetics and Pharmacodynamics of single doses of an oral p38 MAP Kinase Inhibitor (BIRB 796 BS) in healthy human males a placebo-controlled, randomized study, double blinded at each dose level. 58th Ann Mtg of the American Academy of Allergy, Asthma and Immunology, (AAAAI), New York, Mar. 1-6, 2002, J. Allergy Clin Immun. 2002, 109(1) Sup: S67.
Wood, Chester C. et al : Safety, Pharmacokinetics and Pharmacodynamics of an Oral p38 MAP Kinase Inhibitor (BIRB 796 BS), Administered Once Daily for 7 days. Journal of Allergy and Clinical Immunology Online, Jan. 2002, part 2, vol. 109, No. 1.
Zimmitti, C.S., et al: Suppression of p38 activity in vitro and TNF alpha production in vivo with BIRB 796 BS. A novel p38 kinase inhibitor, Arthritis Rheum 2001; ; 44(9):S114, A.
Schwartz, R. et al; Inhibition of p 38 MAP Kinase (MAPK) by BIRB 796 Attenuates Human Neutrophil Activation In Vivo and Inhibits their Influx in Vivo In a Mouse Model of Peritonitis; Arthritis Rheum 2001: 44(9):S114.
Branger, J. et al; Anti-inflammatory effects of a p38 Mitogen activated protein kinase inhibitor (BIRB 796 BS) during human endotoxemia. Arthritis Rheum 2001; 44(9): S164.
Nabozny, G. et al; Inhibition of Established collagen induced arthritis (C(A) with BIB 796, a selective inhibitor of p38 MAP Kinase, Arthritis Rheum 2001; 44(9):S368.
Madwed, J. et al; Pharmacological evaluation of BIRB 796, a selective inhibitor of p38 MAP Kinase (MAPK), in animal models of endotoxic shock, inflammation and arthritis. Inflammation 2001, 5th World Cong. on Inflammation, Edinburgh, Sep. 22-26, 2001 Inflamm Res. 2001;50 (Suppl 3):S184.
Pargellis, C. et al; A novel Series of p38 MAP Kinase Inhibitors: development of a clinical candidate, BIRB 796 Inflammation 2001, 5th World Cong. on Inflammation, Edinburgh, Sep. 22-26, 2001 Inflamm Res. 2001;50 (Suppl 3):S184.
Madwed, J. et al; An in vitro and ex vivo analysis of BIRB 796 BS, a p38 MAP Kinase (MAPK) inhibitor, on Neutrophils in Humans Inflammation 2001, 5th World Cong. on Inflammation, Edinburgh, Sep. 22-26, 2001 Inflamm Res. 2001;50 (Suppl 3):S184.
Branger, J. et al; Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002:168:4070-4077.
Torcellini, C., et al; Pharmacologial evaluation of BIRB 796, a selective inhibitor of p38 MAP Kinase (MAPK), in animal models of endotoxin shock, inflammation and arthritis. Experimental Biol. 2002 Ann. Mta of Prof. Research Scientists, Apr. 20-24, 2002.
New Orleans FASEB J 2002;1695):A1081.
Mealy, N. et al; Dermatologic drugs. Drugs Future 2002; 27(3):289-291.
Cirillo Pier Francesco
Hammach Abdelhakim
Regan John Robinson
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino Anthony P.
Devlin Mary-Ellen M.
Morris Michael P.
Ward Paul V.
LandOfFree
1,4-benzofused urea compounds useful in treating cytokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-benzofused urea compounds useful in treating cytokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-benzofused urea compounds useful in treating cytokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585884